Press Release Details
India: Creating stronger ties with Japanese pharmaceutical industry
New Delhi, April 25, 2015: The Indian pharmaceutical industry recently made a strong impact in Japan. Participating under the Brand India Pharma campaign from the Government of India, Pharmaceutical Export Promotion Council of India (Pharmexcil) led a powerful delegation to Japan and organised a series of initiatives on the sidelines of CPhI Japan. Starting with 5th India-Japan Pharmaceutical Seminar/Business Matching in Osaka on April 20, 2015, Brand India Pharma was strongly represented by Indian pharmaceutical companies at various platforms during April 22-24, 2015. Names like Suven Life Sciences, IndSwift Labs, Jubilant Life Sciences, Laurus Labs, Aurobindo Pharma, Vimta Labs and Simpex Pharma participated under the Brand India Pharma campaign.
The seminar and B2B meetings in Osaka were organised in association with Osaka Prefectural Government, Osaka Industrial Promotion Organization, Indian Drug Manufacturers Association (IDMA) and Osaka Pharmaceutical Manufacturers Association (OPMA). Brand India Pharma also made an impacting presence at CPhI Japan, held from April 22-24, 2015. CPhI Japan was inaugurated at a glittering ceremony at the Big Sight Exhibition Centre in Tokyo, Japan. Mr. Amit Kumar, Deputy Chief of Mission at the Embassy of India in Japan co-inaugurated the Event. In total, close to 42 companies participated from India at CPhI Japan. The India-Japan Pharma Summit organised on the sidelines of CPhI Japan on April 22, 2015 in Tokyo attracted strong participation from the Japanese pharmaceutical industry. With about 280 registered visitors and panellists from the Department of Commerce, Government of India, Pharmexcil, Ministry of Health, Labour & Welfare, Government of Japan, Reva Pharmachem, Aurobindo Pharma, Mitsubishi Tanabe Pharma Corporation, PMDA, Meiji Seika Pharma Co. Ltd, EISAI Co Ltd, Mitsubishi Tanabe Pharma Corporation and Meiji Seika Pharma co Ltd, the India-Japan Pharma Summit was a hugely successful forum. Pharmexcil awarded Japanese companies like Eisai Co Ltd, Meiji Seika Pharma Co Ltd, Mitsubishi Tanabe, Shionogi & Co Ltd for the efforts in the Indian pharmaceutical industry. As part of the planned activities, Pharmexcil partnered with UBM, the organiser of CPhI Japan, for the CPhI Japan 2015 reception. The Reception included a cultural performance on India and a film on the Indian pharmaceutical industry.
"Japan is one of the most important markets for the Indian pharmaceutical industry. We are working with a three-pronged approach in Japan - to boost API exports from India, promote generics from India and position India as a contract manufacturing destination under direct supervision from Japanese companies," said Dr P V Appaji, Director General, Pharmexcil.
Pharmexcil and India Brand Equity Foundation (IBEF) with the support of the Department of Commerce have already worked on a series of initiatives in Japan to expand the presence of Indian pharma industry. The Brand India Pharma campaign was launched at the opening ceremony of CPhI Japan in 2012. Since the launch, IBEF and Pharmexcil have engaged with all the stakeholders including Japanese media, regulators and associations for a deeper engagement with the Japanese pharma sector. The recent initiatives are expected to further deepen the India-Japan engagement in the pharmaceuticals sector.
About Brand India Pharma:
Brand India Pharma campaign is a significant initiative being led by India Brand Equity Foundation (IBEF) and Pharmaceutical Export Promotion Council (Pharmexcil) under the aegis of the Department of Commerce, Government of India, to highlight the value proposition that Brand India Pharma presents today globally. Synonymous with Credible, Affordable and Sustainable healthcare, the Brand India Pharma campaign was launched at CPhI Japan in March 2012.
For any queries, please contact:
Manager - Knowledge Centre
India Brand Equity Foundation
+91 124 4499610